Coronary and Heart Effects of Early Treatment in Familial Hypercholesterolemia

Coronary and Heart Effects of Early Treatment in Familial Hypercholesterolemia - CHEETAH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51451

Enrollment

144

Registered

2022-02-01

Start date

2022-03-07

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

familial hypercholesterolemia

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Diagnosed with heterozygous familial hypercholesterolemia or non-FH control - Adult patients between 25 and 55 years old

Exclusion criteria

Exclusion criteria: - Renal insufficiency, defined as eGFR

Design outcomes

Primary

Measure	Time frame
The main parameter to study will be the total coronary plaque volume.	—

Secondary

Measure	Time frame
The secondary study parameters to be studied will be the following: • Presence of obstructive stenosis (and number of vessels) • Presence of any stenosis (and number of vessels) • Calcified plaque volume • Non-calcified plaque volume • Number and presence of high-risk plaque features, i.e.: o positive remodelling (RI>1.1) o low attenuation plaque (	—

Countries

Netherlands

Outcome results